These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37980528)

  • 1. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.
    Ouyang Y; Ou Z; Zhong W; Yang J; Fu S; Ouyang N; Chen J; Xu L; Wu D; Qian J; Lin Y; Lin T; Huang J
    Cancer Res; 2023 Dec; 83(24):4030-4046. PubMed ID: 37768887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
    Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
    Benítez R; Yu K; Sirota M; Malats N; Pineda S
    Front Immunol; 2023; 14():986598. PubMed ID: 36817478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
    Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
    Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
    Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
    Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
    Jiang W; Zhu D; Wang C; Zhu Y
    Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
    Chen D; Cao H; Zheng X; Wang H; Han Z; Wang W
    BMC Cancer; 2024 Aug; 24(1):1024. PubMed ID: 39160525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.
    Wang Y; Song W; Feng C; Wu S; Qin Z; Liu T; Ye Y; Huang R; Xie Y; Tang Z; Wang Q; Li T
    J Transl Med; 2024 Oct; 22(1):900. PubMed ID: 39367493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
    Noeraparast M; Krajina K; Pichler R; Niedersüß-Beke D; Shariat SF; Grünwald V; Ahyai S; Pichler M
    Cancer Commun (Lond); 2024 Oct; 44(10):1189-1208. PubMed ID: 39161208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma.
    Yuan H; Xiu Y; Liu T; Fan Y; Xu D
    Front Immunol; 2023; 14():1126247. PubMed ID: 37207200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy
    Fan B; Zheng X; Wang Y; Hu X
    Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269
    [No Abstract]   [Full Text] [Related]  

  • 17. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
    Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
    Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
    Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.